What Researchers Did
Researchers conducted a double-blind, placebo-controlled, cross-over study to investigate the effectiveness of hyperbaric oxygen treatment for active cluster headaches.
What They Found
Sixteen patients, including 12 with episodic and four with chronic cluster headache, received two 70-minute treatments at 2.5 ATA, 24 hours apart, with either 100% oxygen or a 10% oxygen placebo. The study found no significant difference between hyperbaric oxygen and placebo in reducing headache attacks or severity. However, 83% of episodic cluster headache patients and 25% of chronic patients responded to either treatment with at least a 50% reduction in headache index or remission.
What This Means for Canadian Patients
This study suggests that hyperbaric oxygen treatment, under the specific protocol tested, may not offer a distinct benefit over a placebo for active cluster headaches. The high response rate to both active and sham treatments, particularly in episodic cases, indicates a strong placebo effect or a non-specific benefit from the hyperbaric environment itself. Canadian patients should discuss all available treatment options with their healthcare providers, as HBOT for cluster headaches is not a Health Canada-recognized indication.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study involved a small number of participants, especially those with chronic cluster headache, which limits the generalizability of the findings.